Management of women with cervicitis

Clinical Infectious Diseases

Volumn 44, Issue SUPPL. 3, 2007, Pages

  Marrazzo, Jeanne M ^a,c   Martin, David H ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMOXICILLIN; AZITHROMYCIN; CEFIXIME; CEFPODOXIME; CEFTRIAXONE; CEFUROXIME AXETIL; CIPROFLOXACIN; DOXYCYCLINE; FAMCICLOVIR; LEVOFLOXACIN; METRONIDAZOLE; OFLOXACIN; VALACICLOVIR;

ANTIBIOTIC THERAPY; ARTICLE; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; FEMALE; HERPES SIMPLEX VIRUS; HUMAN; INFECTION RISK; MYCOPLASMA GENITALIUM; NEISSERIA GONORRHOEAE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SEXUALITY; SINGLE DRUG DOSE; TRICHOMONAS VAGINALIS; UTERINE CERVICITIS; VAGINITIS;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; GONORRHEA; HERPES GENITALIS; HUMANS; MYCOPLASMA INFECTIONS; TRICHOMONAS INFECTIONS; UTERINE CERVICITIS; VAGINOSIS, BACTERIAL;

EID: 33947393569     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/511423     Document Type: Article

References (90)

1. Brunham RC, Paavonen J, Stevens CE, et al. Mucopurulent cervicitis - the ignored counterpart in women of urethritis in men. N Engl J Med 1984; 311:1-6.
2. Rees E, Tait A, Hobson D, Johnson FWA. Chlamydia in relation to cervical infection and pelvic inflammatory disease. In: Hobson D, Holmes KK, eds. Nongonococcal urethritis and related infections. Washington: American Society for Microbiology, 1977:67.
3. Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55(RR-11):1-94.
4. Marrazzo JM, Handsfield HH, Whittington WL. Predicting chlamydial and gonococcal cervical infection: implications for management of cervicitis. Obstet Gynecol 2002; 100:579-84.
5. Marrazzo JM, Johnson RE, Green TA, et al. Impact of patient characteristics on performance of nucleic acid amplification tests and DNA probe for detection of Chlamydia trachomatis in women with genital infections. J Clin Microbiol 2005; 43:577-84.
6. Myziuk L, Romanowski B, Brown M. Endocervical Gram stain smears and their usefulness in the diagnosis of Chlamydia trachomatis. Sex Transm Infect 2001; 77:103-6.
7. Hook EW 3rd, Handsfield HH. Gonococcal infections in the adult. In: Holmes KK, Sparling PF, Mardh P-A, et al., eds. Sexually transmitted diseases. 3rd ed. New York: McGraw-Hill, 1999:451-66.
8. Manavi K, Young H, Clutterbuck D. Sensitivity of microscopy for the rapid diagnosis of gonorrhoea in men and women and the role of gonorrhoea serovars. Int J STD AIDS 2003; 14:390-4.
9. Manavi K, Conlan R, Barrie G. The performance of microscopic cervicitis for the detection of chlamydial infection. Sex Transm Infect 2004; 80:415.
10. Centers for Disease Control and Prevention. 1993 Sexually transmitted diseases treatment guidelines. MMWR Morb Mortal Wkly Rep 1993;42:1-102.
11. Kiviat NB, Paavonen JA, Wolner-Hanssen P, et al. Histopathology of endocervical infection caused by Chlamydia trachomatis, herpes simplex virus, Trichomonas vaginalis, and Neisseria gonorrhoeae. Hum Pathol 1990; 21:831-7.
12. Kiviat NB, Wolner-Hanssen P, Eschenbach DA, et al. Endometrial histopathology in patients with culture-proved upper genital tract infection and laparoscopically diagnosed acute salpingitis. Am J Surg Pathol 1990; 14:167-75.
13. Addiss DG, Vaughn ML, Golubjatnikov R, Pfister J, Kurtycz DF, Davis JP. Chlamydia trachomatis infection in women attending urban mid-western family planning and community health clinics: risk factors, selective screening, and evaluation of non-culture techniques. Sex Transm Dis 1990; 17:138-46.
14. Bertolino JG, Rangel JE, Blake RL Jr, Silverstein D, Ingram E. Inflammation on the cervical Papanicolaou smear: the predictive value for infection in asymptomatic women. Fam Med 1992; 24:447-52.
15. Edelman M, Fox A, Alderman E, et al. Cervical Papanicolaou smear abnormalities and Chlamydia trachomatis in sexually active adolescent females. J Pediatr Adolesc Gynecol 2000; 13:65-9.
16. Garozzo G, Lomeo E, La Greca M, et al. Chlamydia trachomatis diagnosis: a correlative study of pap smear and direct immunofluorescence. Clin Exp Obstet Gynecol 1993; 20:259-63.
17. Hakakha MM, Davis J, Korst LM, Silverman NS. Leukorrhea and bacterial vaginosis as in-office predictors of cervical infection in high-risk women. Obstet Gynecol 2002; 100:808-12.
18. Geisler WM, Yu S, Venglarik M, Schwebke JR. Vaginal leucocyte counts in women with bacterial vaginosis: relation to vaginal and cervical infections. Sex Transm Infect 2004; 80:401-5.
19. Steinhandler L, Peipert JF, Heber W, Montagno A, Cruickshank C. Combination of bacterial vaginosis and leukorrhea as a predictor of cervical chlamydial or gonococcal infection. Obstet Gynecol 2002; 99:603-7.
20. Koumans EH, Johnson RE, Knapp JS, St Louis ME. Laboratory testing for Neisseria gonorrhoeae by recently introduced nonculture tests: a performance review with clinical and public health considerations. Clin Infect Dis 1998; 27:1171-80.
21. Black CM, Marrazzo J, Johnson RE, et al. Head-to-head multicenter comparison of DNA probe and nucleic acid amplification tests for Chlamydia trachomatis infection in women performed with an improved reference standard. J Clin Microbiol 2002; 40:3757-63.
22. Cosentino LA, Landers DV, Hillier SL. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by strand displacement amplification and relevance of the amplification control for use with vaginal swab specimens. J Clin Microbiol 2003; 41:3592-6.
23. Golden MR, Hughes JP, Cles LE, et al. Positive predictive value of Gen-Probe APTIMA Combo 2 testing for Neisseria gonorrhoeae in a population of women with low prevalence of N. gonorrhoeae infection. Clin Infect Dis 2004; 39:1387-90.
24. Shafer MA, Moncada J, Boyer CB, Betsinger K, Flinn SD, Schachter J. Comparing first-void urine specimens, self-collected vaginal swabs, and endocervical specimens to detect Chlamydia trachomatis and Neisseria gonorrhoeae by a nucleic acid amplification test. J Clin Microbiol 2003; 41:4395-9.
25. Schachter J, McCormack WM, Chernesky MA, et al. Vaginal swabs are appropriate specimens for diagnosis of genital tract infection with Chlamydia trachomatis. J Clin Microbiol 2003; 41:3784-9.
26. Chernesky MA, Hook EW 3rd, Martin DH, et al. Women find it easy and prefer to collect their own vaginal swabs to diagnose Chlamydia trachomatis or Neisseria gonorrhoeae infections. Sex Transm Dis 2005; 32:729-33.
27. Schachter J, Chernesky MA, Willis DE, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the AP-TIMA assays for both infections. Sex Transm Dis 2005; 32:725-8.
28. Draper D, Landers D, Krohn M, Hillier S, Wiesenfeld H, Heine R. Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. Am J Obstet Gynecol 2000; 183:1243-8.
29. Fiori PL, Rappelli P, Addis MF. The flagellated parasite Trichomonas vaginalis: new insights into cytopathogenicity mechanisms. Microbes Infect 1999; 1:149-56.
30. Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev 1998; 11:300-17.
31. Schwebke JR. Update of trichomoniasis. Sex Transm Infect 2002; 78:378-9.
32. Huppert JS, Batteiger BE, Braslins P, et al. Use of an immunochromatographic assay for rapid detection of Trichomonas vaginalis in vaginal specimens. J Clin Microbiol 2005; 43:684-7.
33. Corey L, Wald A. Genital herpes. In: Holmes KK SP, Mardh P-A, Lemon SM, Stamm WE, Piot P, Wasserheit J, eds. Sexually transmitted diseases. 3rd ed. New York: McGraw-Hill, 1999:285-312.
34. Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992; 116:433-7.
35. Keshavarz H, Duffy SW, Sadeghi-Hassanabadi A, Zolghadr Z, Oboodi B. Risk factors for and relationship between bacterial vaginosis and cervicitis in a high risk population for cervicitis in Southern Iran. Eur J Epidemiol 2001; 17:89-95.
36. Peipert JF, Montagno AB, Cooper AS, Sung CJ. Bacterial vaginosis as a risk factor for upper genital tract infection. Am J Obstet Gynecol 1997; 177:1184-7.
37. Willmott FE. Mucopurulent cervicitis: a clinical entity? Genitourin Med 1988; 64:169-71.
38. Marrazzo JM, Wiesenfeld HC, Murray P, et al. Risk factors for mucopurulent cervicitis among women with bacterial vaginosis. J Infect Dis 2006; 193:617-24.
39. Schwebke JR, Schulien MB, Zajackowski M. Pilot study to evaluate the appropriate management of patients with coexistent bacterial vaginosis and cervicitis. Infect Dis Obstet Gynecol 1995; 3:119-22.
40. Schwebke JR, Weiss HL. Interrelationships of bacterial vaginosis and cervical inflammation. Sex Transm Dis 2002; 29:59-64.
41. Cu-Uvin S, Hogan JW, Caliendo AM, Harwell J, Mayer KH, Carpenter CC. Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. Clin Infect Dis 2001; 33:894-6.
42. Seck K, Samb N, Tempesta S, et al. Prevalence and risk factors of cervicovaginal HIV shedding among HIV-1 and HIV-2 infected women in Dakar, Senegal. Sex Transm Infect 2001; 77:190-3.
43. Cohen CR, Plummer FA, Mugo N, et al. Increased interleukin-10 in the endocervical secretions of women with non-ulcerative sexually transmitted diseases: a mechanism for enhanced HIV-1 transmission? AIDS 1999; 13:327-32.
44. Cauci S, Guaschino S, De Aloysio D, et al. Interrelationships of interleukin-8 with interleukin-1β and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. Mol Hum Reprod 2003; 9:53-8.
45. Simhan HN, Caritis SN, Krohn MA, Martinez de Tejada B, Landers DV, Hillier SL. Decreased cervical proinflammatory cytokines permit subsequent upper genital tract infection during pregnancy. Am J Obstet Gynecol 2003; 189:560-7.
46. Yudin MH, Landers DV, Meyn L, Hillier SL. Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial. Obstet Gynecol 2003; 102:527-34.
47. Ferris MJ, Masztal A, Aldridge KE, Fortenberry JD, Fidel PL Jr, Martin DH. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis 2004; 4:5.
48. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005; 353:1899-911.
49. Manhart LE, Critchlow CW, Holmes KK, et al. Mucopurulent cervicitis and Mycoplasma genitalium. J Infect Dis 2003; 187:650-7.
50. Schlicht MJ, Lovrich SD, Sartin JS, Karpinsky P, Callister SM, Agger WA. High prevalence of genital mycoplasmas among sexually active young adults with urethritis or cervicitis symptoms in La Crosse, Wisconsin. J Clin Microbiol 2004; 42:4636-40.
51. Cohen CR, Manhart LE, Bukusi EA, et al. Association between Mycoplasma genitalium and acute endometritis. Lancet 2002; 359:765-6.
52. Falk L, Fredlund H, Jensen JS. Tetracycline treatment does not eradicate Mycoplasma genitalium. Sex Transm Infect 2003; 79:318-9.
53. McGalie CE, McBride HA, McCluggage WG. Cytomegalovirus infection of the cervix: morphological observations in five cases of a possibly under-recognised condition. J Clin Pathol 2004; 57:691-4.
54. Zunt JR, Dezzutti CS, Montano SM, et al. Cervical shedding of human T cell lymphotropic virus type I is associated with cervicitis. J Infect Dis 2002; 186:1669-72.
55. Buttigieg G. Cervicitis and urethritis caused by group B streptococcus: case report. Genitourin Med 1985; 61:343-4.
56. Paavonen J, Kiviat N, Brunham RC, et al. Prevalence and manifestations of endometritis among women with cervicitis. Am J Obstet Gynecol 1985; 152:280-6.
57. Paraskevaides EC, Wilson MC. Fatal disseminated intravascular coagulation secondary to streptococcal cervicitis. Eur J Obstet Gynecol Reprod Biol 1988; 29:39-40.
58. Critchlow CW, Wolner-Hanssen P, Eschenbach DA, et al. Determinants of cervical ectopia and of cervicitis: age, oral contraception, specific cervical infection, smoking, and douching. Am J Obstet Gynecol 1995; 173:534-43.
59. Scholes D, Stergachis A, Ichikawa LE, Heidrich FE, Holmes KK, Stamm WE. Vaginal douching as a risk factor for cervical Chlamydia trachomatis infection. Obstet Gynecol 1998; 91:993-7.
60. Kreiss J, Ngugi E, Holmes K, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992; 268:477-82.
61. Richardson BA, Lavreys L, Martin HL. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases. Sex Transm Dis 2001; 28:394-400.
62. Richardson BA. Nonoxynol-9 as a vaginal microbicide for prevention of sexually transmitted infections: it's time to move on. JAMA 2002; 287:1171-2.
63. Wilkinson D, Tholandi M, Ramjee G, Rutherford GW. Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis 2002; 2:613-7.
64. Olmsted SS, Meyn LA, Rohan LC, Hillier SL. Glycosidase and proteinase activity of anaerobic gram-negative bacteria isolated from women with bacterial vaginosis. Sex Transm Dis 2003; 30:257-61.
65. Brabin L. Interactions of the female hormonal environment, susceptibility to viral infections, and disease progression. AIDS Patient Care STDS 2002; 16:211-21.
66. Sobel J. Current concepts: vaginitis. N Engl J Med 1997; 337:1896-903.
67. Hebb JK, Cohen CR, Astete SG, Bukusi EA, Totten PA. Detection of novel organisms associated with salpingitis, by use of 16S rDNA polymerase chain reaction. J Infect Dis 2004; 190:2109-20.
68. Mena L, Wang X, Mroczkowski TF, Martin DH. Mycoplasma genitalium infections in asymptomatic men and men with urethritis attending a sexually transmitted diseases clinic in New Orleans. Clin Infect Dis 2002; 35:1167-73.
69. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002; 51 (RR-6):1-78.
70. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2004. Atlanta: Centers for Disease Control and Prevention, 2005.
71. Screening for gonorrhea: recommendation statement. Ann Fam Med 2005; 3:263-7.
72. Mertz KJ, Levine WC, Mosure DJ, Berman SM, Dorian KJ, Hadgu A. Screening women for gonorrhea: demographic screening criteria for general clinical use. Am J Public Health 1997; 87:1535-8.
73. Miller WC, Ford CA, Morris M, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004; 291:2229-36.
74. Burstein GR, Zenilman JM, Gaydos CA, et al. Predictors of repeat Chlamydia trachomatis infections diagnosed by DNA amplification testing among inner city females. Sex Transm Infect 2001; 77:26-32.
75. Whittington WL, Kent C, Kissinger P, et al. Determinants of persistent and recurrent Chlamydia trachomatis infection in young women: results of a multicenter cohort study. Sex Transm Dis 2001; 28:117-23.
76. Berman SM, Moran JS, Wang SA, Workowski KA. Fluoroquinolones, gonorrhea, and the CDC STD treatment guidelines. Sex Transm Dis 2003; 30:528-9; author reply, 530.
77. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men - United States, 2003, and revised recommendations for gonorrhea treatment, 2004. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 2004; 53: 335-8.
78. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007; 44(Suppl 3):S84-101 (in this supplement).
79. Nyirjesy P. Nongonococcal and nonchlamydial cervicitis. Curr Infect Dis Rep 2001; 3:540-5.
80. Paavonen J, Critchlow CW, DeRouen T, et al. Etiology of cervical inflammation. Am J Obstet Gynecol 1986; 154:556-64.
81. Gaydos CA, Hardick A, Hardick J, Barnes M, Wood BJ. Use of Gen-Probe APTIMA tests to detect multiple etiologies of urethritis and cervicitis in sexually transmitted disease clinics [abstract C-086]. In: Program and abstracts of the American Society for Microbiology 106th General Meeting (Orlando, FL). Washington, DC: American Society for Microbiology, 2006:63.
82. Nugent RP, Hillier SL. Mucopurulent cervicitis as a predictor of chlamydial infection and adverse pregnancy outcome. The Investigators of the Johns Hopkins Study of Cervicitis and Adverse Pregnancy Outcome. Sex Transm Dis 1992; 19:198-202.
83. Peipert JF, Ness RB, Soper DE, Bass D. Association of lower genital tract inflammation with objective evidence of endometritis. Infect Dis Obstet Gynecol 2000; 8:83-7.
84. Wiesenfeld HC, Hillier SL, Krohn MA, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002; 100:456-63.
85. Stamm WE, Hicks CB, Martin DH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men: a randomized double-blind study. JAMA 1995; 274:545-9.
86. Paavonen J, Roberts PL, Stevens CE, et al. Randomized treatment of mucopurulent cervicitis with doxycycline or amoxicillin. Am J Obstet Gynecol 1989; 161:128-35.
87. Chandeying V, Sutthijumroon S, Tungphaisal S. Evaluation of ofloxacin in the treatment of mucopurulent cervicitis: a response of chlamydia-positive and chlamydia-negative forms. J Med Assoc Thai 1989; 72: 331-7.
88. Stekler J, Bachmann L, Brotman RM, et al. Concurrent sexually transmitted infections (STIs) in sex partners of patients with selected STIs: implications for patient-delivered partner therapy. Clin Infect Dis 2005; 40:787-93.
89. Wright TC Jr, Subbarao S, Ellerbrock TV, et al. Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol 2001; 184:279-85.
90. McClelland RS, Wang CC, Mandaliya K, et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001; 15:105-10.